1
|
Larrue R, Fellah S, Van der Hauwaert C, Hennino MF, Perrais M, Lionet A, Glowacki F, Pottier N, Cauffiez C. The Versatile Role of miR-21 in Renal Homeostasis and Diseases. Cells 2022; 11:cells11213525. [PMID: 36359921 PMCID: PMC9657972 DOI: 10.3390/cells11213525] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 11/03/2022] [Accepted: 11/04/2022] [Indexed: 11/09/2022] Open
Abstract
MicroRNAs (miRNAs) are small, non-coding RNA species that control gene expression and confer robustness to biological processes. Over the last two decades, their important roles during kidney development, homeostasis and the treatment of diseases have been established, in particular during the onset and progression of various forms of acute and chronic renal disorders. In recent years, miR-21, one of the best-characterized miRNAs to date, has received much attention in renal physiology in particular given its high degree of conservation and expression in kidneys, as well as its potent pathogenic role in various debilitating renal diseases. This review summarizes the current knowledge on miR-21’s involvement in both renal homeostasis and diseases, in particular its double-edged-sword role in acute versus chronic kidney injuries. Finally, we also discuss the potential of miR-21 as a biomarker and therapeutic target in renal diseases.
Collapse
Affiliation(s)
- Romain Larrue
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Sandy Fellah
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Cynthia Van der Hauwaert
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
- CHU Lille, Département de la Recherche en Santé, F-59000 Lille, France
| | | | - Michaël Perrais
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Arnaud Lionet
- CHU Lille, Service de Néphrologie, F-59000 Lille, France
| | - François Glowacki
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
- CHU Lille, Service de Néphrologie, F-59000 Lille, France
| | - Nicolas Pottier
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Christelle Cauffiez
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
- Correspondence:
| |
Collapse
|
2
|
Dauvergne M, Buob D, Rafat C, Hennino MF, Lemoine M, Audard V, Chauveau D, Ribes D, Cornec-Le Gall E, Daugas E, Pillebout E, Vuiblet V, Boffa JJ. Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review. Clin Kidney J 2021; 14:2563-2572. [PMID: 34950468 PMCID: PMC8690152 DOI: 10.1093/ckj/sfab114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 05/28/2021] [Indexed: 12/29/2022] Open
Abstract
Background The spectrum of interferon-β (IFN-β)-associated nephropathy remains poorly described and the potential features of this uncommon association remain to be determined. Methods In this study we retrospectively analysed the clinical, laboratory, histological and therapeutic data of patients with biopsy-proven renal disease in a context of IFN-β treatment administered for at least 6 months. Results Eighteen patients (13 women, median age 48 years) with biopsy-proven renal disease occurring during IFN-β therapy were included. The median exposure to IFN-β (14 patients were treated with IFN-β1a and 4 patients with IFN-β1b) was 67 months (range 23–165 months). The clinical presentation consists in hypertension (HT; 83%), malignant HT (44%), proteinuria (protU) >1 g/g (94%), reduced renal function (78%), biological hallmark suggesting thrombotic microangiopathy (TMA; 61%), oedematous syndrome (17%) or nephritic syndrome (11%). The pathological findings included typical features of isolated TMAs in 11 cases, isolated focal segmental glomerulosclerosis (FSGS) lesions in 2 cases and 5 cases with concomitant TMA and FSGS lesions. An exploration of the alternative complement pathway performed in 10 cases (63%) did not identify mutations in genes that regulate the complement system. The statistical analysis highlighted that the occurrence of IFN-β-associated TMA was significantly associated with Rebif, with a weekly dose >50 µg and with multiple weekly injections. In all cases, IFN-β therapy was discontinued. Patients with TMA lesions received other therapies, including corticosteroids (44%), eculizumab (13%) and plasma exchanges (25%). At the end of a 36-month median follow-up, persistent HT and persistent protU were observed in 61% and 22% of patients, respectively. Estimated glomerular filtration rate <60 mL/min/1.73 m2 was present in 61% of patients. Conclusions IFN-β-associated nephropathy must be sought in the case of HT and/or protU onset during treatment. When TMA and/or FSGS are observed on renal biopsy, early discontinuation of IFN-β is essential.
Collapse
Affiliation(s)
- Maxime Dauvergne
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Néphrologie et Dialyses, Paris, France
| | - David Buob
- Institut National de la Santé et de la Recherche Médicale, Paris, France
| | - Cédric Rafat
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Urgences Néphrologiques et Transplantation Rénale, Paris, France
| | - Marie-Flore Hennino
- Centre Hospitalier de Valenciennes, Service de Néphrologie, Valenciennes, France
| | - Mathilde Lemoine
- CHU de Rouen, Service de Néphrologie, Dialyse et Transplantation, Rouen, France
| | - Vincent Audard
- Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Créteil, France
| | - Dominique Chauveau
- CHU Rangueil, Département de Néphrologie et Transplantation d'Organes et Centre de Référence Maladies Rénales Rares SORARE, Toulouse, France
| | - David Ribes
- CHU Rangueil, Département de Néphrologie et Transplantation d'Organes et Centre de Référence Maladies Rénales Rares SORARE, Toulouse, France
| | | | - Eric Daugas
- Assistance Publique des Hôpitaux de Paris, Hôpital Bichat, Service de Néphrologie, Paris, France
| | - Evangéline Pillebout
- Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Service de Néphrologie, Paris, France
| | - Vincent Vuiblet
- Département de Néphro-Pathologie, Unité de Pathologie, CHU Reims, Reims, France
| | - Jean-Jacques Boffa
- Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service de Néphrologie et Dialyses, Paris, France
| | | |
Collapse
|
3
|
Hennino MF, Buob D, Van der Hauwaert C, Gnemmi V, Jomaa Z, Pottier N, Savary G, Drumez E, Noël C, Cauffiez C, Glowacki F. miR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy. Sci Rep 2016; 6:27209. [PMID: 27264483 PMCID: PMC4893709 DOI: 10.1038/srep27209] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Accepted: 05/11/2016] [Indexed: 12/24/2022] Open
Abstract
IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis, whose prognosis is highly variable. Interstitial fibrosis is a strong independent prognosis factor. Among microRNA involved in renal fibrogenesis, only few have been investigated in IgAN. In the context of IgAN, we aimed to analyze the role of miR-21-5p, miR-214-3p and miR-199a-5p, three established "fibromiRs" involved in renal fibrosis. Fifty-six IgAN biopsy specimens were retrospectively scored according to Oxford classification. Renal expression of miR-21-5p, miR-214-3p and miR-199a-5p were significantly associated with T score (miR-21-5p T0 RQ median = 1.23, T1 RQ = 3.01, T2 RQ = 3.90; miR-214-5p T0 RQ = 1.39, T1 RQ = 2.20, T2 RQ = 2.48; miR-199a-5p T0 RQ = 0.76, T1 RQ = 1.41, T2 RQ = 1.87). miR-21-5p expression was associated with S score (S0 RQ median = 1.31, S1 RQ = 2.65), but not miR-214-3p nor miR-199a-5p. In our cohort, poor renal survival was associated with high blood pressure, proteinuria and elevated creatininemia, as well as T and S scores. Moreover, renal expression of miR-21-5p, miR-214-3p were associated with renal survival. In conclusion, miR-21-5p, miR-214-3p and miR-199a-5p are three "fibromiRs" involved in renal fibrosis in the course of IgAN and miR-21-5p and miR-214-3p are associated with renal survival.
Collapse
Affiliation(s)
- Marie-Flore Hennino
- Univ. Lille, CHU Lille - Service de néphrologie, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact of Environmental ChemicalS on human health, F-59000 Lille, France.,Centre Hospitalier de Valenciennes - Service de néphrologie, médecine interne et vasculaire, F-59300 Valenciennes, France
| | - David Buob
- Sorbonne Universités, UPMC Paris 06, Inserm, AP-HP, Hôpital Tenon, Pathology Department, UMR S 1155, F-75020 Paris, France
| | - Cynthia Van der Hauwaert
- Univ. Lille, CHU Lille - Service de néphrologie, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact of Environmental ChemicalS on human health, F-59000 Lille, France
| | - Viviane Gnemmi
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Zacharie Jomaa
- Centre Hospitalier de Cambrai - Service de néphrologie, F-59400 Cambrai, France
| | - Nicolas Pottier
- Univ. Lille, CHU Lille - Service de néphrologie, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact of Environmental ChemicalS on human health, F-59000 Lille, France
| | - Grégoire Savary
- Univ. Lille, CHU Lille - Service de néphrologie, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact of Environmental ChemicalS on human health, F-59000 Lille, France
| | - Elodie Drumez
- Univ. Lille, CHU Lille, EA 2694 - Santé publique: épidémiologie et qualité des soins, F-59000 Lille, France
| | - Christian Noël
- Univ. Lille, Inserm, CHU Lille - Service de néphrologie, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Christelle Cauffiez
- Univ. Lille, CHU Lille - Service de néphrologie, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact of Environmental ChemicalS on human health, F-59000 Lille, France
| | - François Glowacki
- Univ. Lille, CHU Lille - Service de néphrologie, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact of Environmental ChemicalS on human health, F-59000 Lille, France
| |
Collapse
|
4
|
Abstract
Renal fibrosis represents the final stage of most chronic kidney diseases and contributes to the progressive and irreversible decline in kidney function with accumulation of extracellular matrix components in the renal parenchyma. The molecular mechanisms governing the renal fibrosis process are complex and remain poorly understood. Recently, the profibrotic role of several microRNAs (miRNAs) has been described in kidney fibrosis. MiRNAs are a new class of, small non-coding RNAs of about 20 nucleotides that act as gene expression negative regulators at the post-transcriptional level. Seminal studies have highlighted the potential importance of miRNA as new therapeutic targets and innovative diagnostic and/or prognostic biomarkers. This review summarizes recent scientific advances on the role played by miRNAs in kidney fibrogenesis and discusses potential clinical applications as well as future research directions.
Collapse
Affiliation(s)
- Cynthia Van der Hauwaert
- EA4483, pôle recherche, faculté de médecine de Lille, université de Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - Grégoire Savary
- EA4483, pôle recherche, faculté de médecine de Lille, université de Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - Marie-Flore Hennino
- EA4483, pôle recherche, faculté de médecine de Lille, université de Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - Nicolas Pottier
- EA4483, pôle recherche, faculté de médecine de Lille, université de Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - François Glowacki
- EA4483, pôle recherche, faculté de médecine de Lille, université de Lille, 1, place de Verdun, 59045 Lille cedex, France; Service de néphrologie, hôpital Huriez, CHRU de Lille, boulevard Michel-Polonovski, 59037 Lille cedex, France.
| | - Christelle Cauffiez
- EA4483, pôle recherche, faculté de médecine de Lille, université de Lille, 1, place de Verdun, 59045 Lille cedex, France
| |
Collapse
|